Perspectives on Ulcerative Colitis in Europe

Goal Statement
The goal of the 2016-2017 Xpert Perspectives on Ulcerative Colitis in Europe On-Demand Series is to deliver focused updates highlighting the most clinically relevant advances in treatment decisions for patients with UC throughout Europe.

Target Audience
The target audiences for this initiative are gastroenterologists, specialist nurses and general practitioners. Siyemi and the GiHF believe this program will enhance the professional effectiveness of program participants of treating their patients with ulcerative colitis, benefiting patients under their care.

Educational Objectives
Upon completion of this activity, participants should be better able to:

    Develop strategies to select the optimal therapeutic goal and treatment choices for UC
    Describe the effect that UC has on patient quality of life
    Implement strategies for incorporating recently approved and emerging therapies for UC
    Define 'biosimilars' and discuss the scientific concept, 'real world' data and benefits
    Analyze recently approved and emerging therapies for UC

Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Siyemi Learning and GI Health Foundation.

Siyemi Learning is accredited by the ACCME to provide continuing medical education for physicians. Siyemi Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date: June 6th, 2017
Expiration Date: June 6th, 2018

Disclosure statement
Yago González Lama, MD:
Advisory Board: Janssen and AbbVie
Speaker: Pfizer, Janssen, AbbVie and Takeda
Honorarium Recipient: Shire

Julian Panes, MD:
Consultant: AbbVie, Boehringer-Ingelheim, Celgene, GSK, Janssen, MSD, Novartis, Pfizer, Roche, Secon Genome, Takeda and TiGenix
Grant Recipient: AbbVie and MSD
Speakers' Bureau: Ferring, Pfizer, Janssen, MSD

All staff at Siyemi Learning and GiHF have no relevant financial relationships to disclose.